denkapparat Operations GmbH Purchases Shares of 1,758 DaVita Inc. (NYSE:DVA)

denkapparat Operations GmbH bought a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,758 shares of the company's stock, valued at approximately $263,000.

Other hedge funds have also recently made changes to their positions in the company. Amundi raised its holdings in DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after buying an additional 240,126 shares during the last quarter. FMR LLC raised its holdings in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after acquiring an additional 116,758 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Finally, Strategic Financial Concepts LLC bought a new stake in shares of DaVita in the 4th quarter worth $9,371,000. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

Shares of NYSE:DVA traded up $2.78 during trading on Wednesday, hitting $154.69. The company's stock had a trading volume of 209,097 shares, compared to its average volume of 807,017. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The firm has a market cap of $12.38 billion, a price-to-earnings ratio of 14.40, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a 50-day moving average of $156.77 and a 200-day moving average of $157.44. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on DVA shares. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. StockNews.com cut shares of DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.